ROGERS JOHN W JR purchased $264K of RYAN

ROGERS JOHN W JR purchased 7,500 shares of RYAN SPECIALTY HOLDINGS, INC. (RYAN) at $35.16 ($0.26M total) on 2026-06-10.

Original reporting
SEC EDGAR · ROGERS JOHN W JR
Published Jun 11, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RYAN
Bullish
medium confidence
Mentioned
$RYAN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RYANBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase amount, price, and post-transaction holdings; it may slightly influence sentiment but does not change fundamentals on its own.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no new operational or financial catalyst in the text.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context (e.g., prior trading history, motivation, or whether other insiders/owners acted).

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-11; purchase dated 2026-06-10.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for RYAN Specialty Holdings, Inc.

Company-level read

Ticker impact

$RYANBullishMedium confidence
Context

Director John W. Rogers Jr. filed an SEC Form 4 for an open-market purchase of 7,500 shares of RYAN Specialty at $35.1643/share on 2026-06-10.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with no accompanying guidance, deal, or regulatory development; size is moderate relative to typical market-moving events.

Market effects

No clear sector read-across; this is company-specific insider activity without operational or regulatory details.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or pre-planned behavior rather than a strong forward-looking view.

Key entities

  • RYAN Specialty Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • ROGERS JOHN W JR

    Director who purchased 7,500 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.